MX2007013834A - Terapias de enfermedades vasculares. - Google Patents

Terapias de enfermedades vasculares.

Info

Publication number
MX2007013834A
MX2007013834A MX2007013834A MX2007013834A MX2007013834A MX 2007013834 A MX2007013834 A MX 2007013834A MX 2007013834 A MX2007013834 A MX 2007013834A MX 2007013834 A MX2007013834 A MX 2007013834A MX 2007013834 A MX2007013834 A MX 2007013834A
Authority
MX
Mexico
Prior art keywords
vascular disease
disease therapies
agents
methods
vascular
Prior art date
Application number
MX2007013834A
Other languages
English (en)
Inventor
David Y Liu
Ingrid Langsetmo Parobok
Christopher T Jacob
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of MX2007013834A publication Critical patent/MX2007013834A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a metodos y agentes para tratar funcion cardiaca y vascular deteriorada. Tambien se proporcionan metodos y agentes para tratar varias caracteristicas fisiologicas y patologicas asociadas con disfuncion vascular y disfuncion cardiaca.
MX2007013834A 2005-05-05 2006-05-05 Terapias de enfermedades vasculares. MX2007013834A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67849505P 2005-05-05 2005-05-05
US69095705P 2005-06-15 2005-06-15
US73443305P 2005-11-07 2005-11-07
PCT/US2006/017759 WO2006122046A2 (en) 2005-05-05 2006-05-05 Vascular disease therapies

Publications (1)

Publication Number Publication Date
MX2007013834A true MX2007013834A (es) 2008-02-05

Family

ID=36778299

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2007013819A MX2007013819A (es) 2005-05-05 2006-05-05 Terapias de enfermedades cardiovasculares.
MX2007013834A MX2007013834A (es) 2005-05-05 2006-05-05 Terapias de enfermedades vasculares.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2007013819A MX2007013819A (es) 2005-05-05 2006-05-05 Terapias de enfermedades cardiovasculares.

Country Status (10)

Country Link
US (3) US8088381B2 (es)
EP (2) EP1885756A2 (es)
JP (2) JP2008540456A (es)
AU (2) AU2006244148A1 (es)
CA (2) CA2606778A1 (es)
IL (2) IL187113A (es)
MX (2) MX2007013819A (es)
NO (2) NO20076121L (es)
NZ (1) NZ563493A (es)
WO (2) WO2006122047A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098065A2 (en) * 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Human sodium channel isoforms
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US20080075666A1 (en) * 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
US9050350B2 (en) 2007-10-18 2015-06-09 U.S. Department Of Veterans Affairs Method for modulating or controlling connexin 43(Cx43) level of a cell and reducing arrhythmic risk
US9114151B2 (en) * 2007-10-18 2015-08-25 The United States Of America Dept. Of Veterans Affairs Method for modulating or controlling sodium channel current by reactive oxygen species (ROS) originating from mitochondria
US9211301B2 (en) 2007-10-18 2015-12-15 U.S. Department Of Veterans Affairs Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy by improving conduction velocity
US9220720B2 (en) 2007-10-18 2015-12-29 U.S. Department Of Veterans Affairs Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy
DK2331141T3 (en) 2008-08-25 2016-04-04 Excaliard Pharmaceuticals Inc Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
WO2010032007A1 (en) * 2008-09-18 2010-03-25 Universitetet I Oslo Use of ctgf as a cardioprotectant
US20110262398A1 (en) * 2010-04-21 2011-10-27 University Of Illinois Cardiac treatment using anti-fibrotic agents
KR101249041B1 (ko) * 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
TWI593416B (zh) 2011-02-02 2017-08-01 艾克厘德製藥公司 利用針對結締組織生長因子（ｃｔｇｆ）目標之反義化合物治療瘢痕或肥厚性疤痕之方法
DE102012103096A1 (de) * 2012-04-11 2013-10-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Prophylaxe und Behandlung einer Gefäßkalzifizierung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US7384634B2 (en) * 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
JPH11180895A (ja) 1997-09-12 1999-07-06 Masaharu Takigawa 血管新生阻害剤
AU1682699A (en) 1997-12-25 1999-07-19 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US20010006979A1 (en) 1998-07-08 2001-07-05 Richard Stratton Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
US6492129B1 (en) 1998-12-14 2002-12-10 University Of Miami Fragments of connective tissue growth factor that induce extracellular matrix synthesis, collagen synthesis and/or myofibroblast differentiation
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
ES2398039T3 (es) * 2000-03-09 2013-03-13 Genzyme Corporation Uso de anticuerpos antagonistas anti-TGF-beta para tratar o prevenir la pérdida de función renal
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
CN1602207A (zh) * 2001-12-11 2005-03-30 法布罗根股份有限公司 抑制眼病理过程的方法
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
ES2311973T3 (es) 2004-02-11 2009-02-16 Fibrogen, Inc. Ctgf como objetivo para la terapia de microalbuminuria en pacientes con nefropatia diabetica.

Also Published As

Publication number Publication date
WO2006122046A2 (en) 2006-11-16
US8088381B2 (en) 2012-01-03
CA2607044A1 (en) 2006-11-16
EP1885756A2 (en) 2008-02-13
US20060281668A1 (en) 2006-12-14
NZ563493A (en) 2010-10-29
IL187113A0 (en) 2008-02-09
US20120039882A1 (en) 2012-02-16
WO2006122047A1 (en) 2006-11-16
JP5068253B2 (ja) 2012-11-07
CA2606778A1 (en) 2006-11-16
EP1891109A1 (en) 2008-02-27
AU2006244147A1 (en) 2006-11-16
MX2007013819A (es) 2008-02-05
NO20076241L (no) 2008-02-04
IL187113A (en) 2011-06-30
AU2006244148A1 (en) 2006-11-16
US20060281667A1 (en) 2006-12-14
JP2008540456A (ja) 2008-11-20
JP2008540457A (ja) 2008-11-20
IL187115A0 (en) 2008-02-09
NO20076121L (no) 2008-02-04
WO2006122046A3 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
MX2007013834A (es) Terapias de enfermedades vasculares.
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
TW200640488A (en) Extending time to disease progression or survival in cancer patients
HK1207821A1 (en) Improved modalities for the treatment of degenerative diseases of the retina
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
WO2006127900A3 (en) Tl1a in the treatment of disease
UA85559C2 (en) Aminobenzophenone compounds
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
WO2009149485A3 (en) Compounds for treating amyloidoses
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
IL186491A0 (en) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
WO2007005502A3 (en) Methods and compositions for treating diseases targeting cdcp1
UA96926C2 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
GB0416508D0 (en) Therapeutic agents
EP1636160A4 (en) NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLISM AND SKIN DISEASES
GB0523961D0 (en) The treatment of ophthalmic diseases
EP1755670A4 (en) METHODS FOR TREATING VASCULAR DISEASES
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
WO2006019978A3 (en) Compositions and methods for diagnosis and treatment of epilepsy
GB0410238D0 (en) Therapeutic agents
IL185653A (en) Antibodies that call for the 1-kim salt region
WO2007048034A3 (en) Use of androgens for the treatment of parkinson' s disease
IL182353A0 (en) Methods using glycosaminoglycans for the treatment of kidney disease

Legal Events

Date Code Title Description
FA Abandonment or withdrawal